-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Collegium Pharmaceutical, Inc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2019 to Q3 2025.
- Collegium Pharmaceutical, Inc Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $11.9M, a 91% increase year-over-year.
- Collegium Pharmaceutical, Inc Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $22.4M, a 43.1% decline year-over-year.
- Collegium Pharmaceutical, Inc annual Income Tax Expense (Benefit) for 2024 was $29.4M, a 6.53% increase from 2023.
- Collegium Pharmaceutical, Inc annual Income Tax Expense (Benefit) for 2023 was $27.6M.
- Collegium Pharmaceutical, Inc annual Income Tax Expense (Benefit) for 2022 was -$3.85M, a 94.9% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)